Търсене на изпитвания

AI · Cancer

Намерени 1,993 изпитвания за "Cancer" Стр. 91 от 100

Активно (без набиране) Фаза 3

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

Advanced/Metastatic Gastroesophageal Adenocarcinoma

The purpose of this study is to assess the efficacy and safety of lenvatinib (E7080/MK-7902) plus pembrolizumab (MK-3475) plus chemotherapy compared with chemotherapy alone in participants with advanced/metastatic gastroesophageal cancer. The primary study hypotheses are that lenvatinib plus pembrolizumab plus chemotherapy is superior to chemotherapy alone for both overall survival (OS) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR), in participants with programmed cell death-ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 and in all participants.

Начало: 30.12.2020 Край: 31.03.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +20 Merck Sharp & Dohme LLC NCT04662710

Активно (без набиране) Фаза 2

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

Urinary Bladder Neoplasms

The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab (Cohort 1), or TAR-200 alone (Cohort 2), or cetrelimab alone (Cohort 3) with Carcinoma in Situ (CIS), with or without concomitant high-grade Ta or T1 papillary disease; and disease-free survival (DFS) in participants treated with TAR-200 alone with papillary disease only (Cohort 4).

Начало: 18.12.2020 Край: 30.09.2027 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +13 Janssen Research & Development, LLC NCT04640623

Активно (без набиране) Фаза 3

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

Urinary Bladder Neoplasms

The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV) cetrelimab versus concurrent chemoradiotherapy.

Начало: 07.12.2020 Край: 31.12.2028 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +20 Janssen Research & Development, LLC NCT04658862

Активно (без набиране) Фаза 3

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

Prostatic Neoplasms

The main purpose of this study is to determine if the addition of apalutamide to radiotherapy (RT) plus luteinizing hormone-releasing hormone agonist (LHRHa) delays metastatic progression as assessed by prostate specific membrane antigen-positron emission tomography (PSMA-PET) or death compared with RT plus LHRHa alone.

Начало: 12.11.2020 Край: 27.08.2029 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +15 Janssen Pharmaceutica N.V., Belgium NCT04557059

Активно (без набиране)

Supportive Oncology Care At Home RCT

Pancreatic Cancer GastroEsophageal Cancer Rectal Cancer Head and Neck Cancer +1

This research study is evaluating a program that entails remote monitoring and home-based care for people with cancer who are receiving chemotherapy, radiotherapy, or chemoradiotherapy.

Начало: 16.09.2020 Край: 31.12.2026 Възраст: от 18 г.

United States Massachusetts General Hospital NCT04544046

Активно (без набиране) Фаза 3

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

Myelofibrosis (MF)

Myelofibrosis (MF) is a rare blood cancer, notable for scarring of the bone marrow (the spongy tissue inside bones) and the spleen becoming larger. The purpose of this study is to assess safety and change in spleen volume when navitoclax is given in combination with ruxolitinib, compared to best available therapy, for adult participants with MF. Navitoclax is an investigational drug (not yet approved) being developed for the treatment of MF. Participants in this study will be randomly selected (like picking numbers out of a hat) to be in 1 of 2 treatment arms. Neither participants nor the study doctor will be able to pick which treatment arm a participants enters. In Arm A, participants will receive navitoclax in combination with ruxolitinib. In Arm B, participants will receive the best available therapy (BAT) for MF. In Arm C, participants will receive navitoclax. Adult participants with a diagnosis of MF that came back or did not get better after earlier treatment will be enrolled. Approximately 330 participants will be enrolled in approximately 322 sites across the world. In Arm A, participants will receive navitoclax tablet by mouth once daily with by mouth ruxolitinib tablet twice daily. In Arm B, participants will receive the BAT available to the investigator. In Arm C, participants will receive navitoclax tablet by mouth once daily. Participants will receive the study drug until they experience no benefit (determined by the investigator), participants cannot tolerate the study drugs, or participants withdraw consent. The approximate treatment duration is about 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of treatment will be checked by medical assessments, blood and bone marrow tests, checking for side effects, and completing questionnaires.

Начало: 31.08.2020 Край: 01.12.2026 Възраст: от 18 г. Лечение

Australia, Belgium, Bulgaria +24 AbbVie NCT04468984

Активно (без набиране) Фаза 3

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Diffuse Large B-cell Lymphoma

Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment. The trial will study whether brentuximab vedotin plus two drugs works better to treat this type of cancer than the two drugs alone. Participants will be randomly assigned to get either brentuximab vedotin or placebo. The placebo will look like brentuximab vedotin, but has no medicine in it. Since the study is "blinded," participants and their doctors will not know whether a participant gets brentuximab vedotin or placebo. All participants in the study will get rituximab and lenalidomide. These are drugs that can be used to treat DLBCL.

Начало: 20.08.2020 Край: 31.12.2026 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +11 Seagen, a wholly owned subsidiary of Pfizer NCT04404283

Активно (без набиране) Фаза 1/2

Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy

Prostatic Neoplasms

This clinical trial will evaluate the dosimetry, efficacy and toxicity of Lu-PSMA in men with high PSMA-expressing high-risk localized or locoregional advanced prostate cancer (HRCaP) undergoing radical prostatectomy (RP) and pelvic lymph node dissection (PLND)

Начало: 06.08.2020 Край: 30.08.2025 Възраст: от 18 г. Лечение

Australia Peter MacCallum Cancer Centre, Australia NCT04430192

Активно (без набиране) Фаза 2

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

Recurrent Ependymoma Recurrent Ewing Sarcoma Recurrent Hepatoblastoma Recurrent Langerhans Cell Histiocytosis +29

This phase II Pediatric MATCH trial studies how well ivosidenib works in treating patients with solid tumors, including central nervous system tumors, lymphomas and histiocytic disorders that have not responded to (refractory) or have come back after (recurrent) prior treatment that have IDH (isocitrate dehydrogenase) 1 genetic alterations (mutations). Ivosidenib may block the growth of cancer cells that have specific genetic changes in an important signaling pathway called the IDH pathway.

Начало: 20.07.2020 Край: 09.05.2026 Възраст: 12–21 г. Лечение

Australia, Puerto Rico, United States National Cancer Institute (NCI) NCT04195555

Активно (без набиране) Фаза 3

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Relapsed/Refractory Follicular Lymphoma Follicular Lymphoma Refractory Follicular Lymphoma

The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after a period of improvement after that follows a treatment regimen and 'refractory' when treatment no longer works. Stage 1 of this trial will study the safety and the level that adverse effects of each of the study drug combinations can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for stage 2 and 3. Stage 1 of the study is completed. Stages 2 and 3 will evaluate and compare how long participants live without their disease getting worse when receiving the study drug in combination with other drug treatment versus the placebo (dummy drug) in combination with other drug treatment.

Начало: 11.06.2020 Край: 01.03.2029 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +14 Epizyme, Inc. NCT04224493

Активно (без набиране) Фаза 1

Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM

Glioblastoma Multiforme

This phase I trial studies the side effects of stereotactic radiosurgery with MBG453 and spartalizumab in treating patients with recurrent glioblastoma multiforme (GBM). Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor to more precisely target the cancer. Monoclonal antibodies, such as MBG453 and spartalizumab may interfere with the ability of tumor cells to grow and spread. Giving stereotactic radiosurgery together with immunotherapy may be a better treatment for GBM.

Начало: 18.02.2020 Край: 01.09.2026 Възраст: от 18 г.

United States Sidney Kimmel Comprehensive Cancer Center at Johns Hopk NCT03961971

Активно (без набиране) Фаза 3

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Non-Small Cell Lung Cancer

This Phase III study will be conducted to evaluate the efficacy and safety of YH25448 as first-line treatment in locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) patients with EGFR mutations

Начало: 13.02.2020 Край: 01.06.2026 Възраст: от 18 г. Лечение

Australia, Greece, Hungary +10 Yuhan Corporation NCT04248829

Активно (без набиране) Фаза 1/2

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

Desmoplastic Small Round Cell Tumor

This study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory desmoplastic small round cell tumor (DSRCT) in children and young adults. This trial is part of the CAMPFIRE master protocol (NCT05999994) which is a platform to accelerate the development of new treatments for pediatric and young adult participants with cancer. Your participation in this trial could last 12 months or longer, depending on how you and your tumor respond.

Начало: 22.01.2020 Край: 01.10.2026 Възраст: 12–29 г. Лечение

Australia, Germany, Italy +4 Eli Lilly and Company NCT04145349

Активно (без набиране)

Liver Ablative Radiotherapy Utilising Kilovoltage Intrafraction Monitoring (KIM)

Liver Cancer

Primary and secondary liver cancer patients will receive liver SABR with or without KIM intervention.

Начало: 14.01.2020 Край: 01.01.2026 Възраст: 18–85 г. Лечение

Australia University of Sydney NCT02984566

Активно (без набиране) Фаза 2

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma (HNSCC)

The aim of this study is to potentiate adaptive immunity to enhance the anti-tumor activity of anti-PD1 antibody by the addition of anti-CTLA4 antibody or anti-LAG3 antibody (relatlimab) given in subjects with resectable locally advanced HNSCC prior to surgical resection.

Начало: 20.12.2019 Край: 17.10.2026 Възраст: от 18 г.

United States Dan Zandberg NCT04080804

Активно (без набиране) Фаза 3

Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Patients With Resected Metastatic Brain Disease

Metastatic Malignant Neoplasm in the Brain

This phase III trial studies how well single fraction stereotactic radiosurgery works compared with fractionated stereotactic radiosurgery in treating patients with cancer that has spread to the brain from other parts of the body and has been removed by surgery. Single fraction stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Fractionated stereotactic radiosurgery delivers multiple, smaller doses of radiation therapy over time. This study may help doctors find out if fractionated stereotactic radiosurgery is better or worse than the usual approach with single fraction stereotactic radiosurgery.

Начало: 19.11.2019 Край: 01.09.2028 Възраст: от 18 г.

Canada, United States Alliance for Clinical Trials in Oncology NCT04114981

Активно (без набиране) Фаза 2

Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

Solid Tumors

The purpose of this study is to assess the efficacy and safety of treatment with olaparib (MK-7339) in combination with pembrolizumab (MK-3475) in adults with previously treated, advanced (metastatic and/or unresectable) Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-positive solid tumors.

Начало: 18.11.2019 Край: 29.06.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Canada +20 Merck Sharp & Dohme LLC NCT04123366

Активно (без набиране)

Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer

Metastatic Tumors

Stereotactic Ablative Radiotherapy (SABR) is a modern RT technique that delivers high doses of radiation to small tumor targets using highly conformal techniques. SABR is non-invasive and delivered on an outpatient basis. The purpose of this study is to compare the effect of SABR, relative to standard of care (SOC) alone, on overall survival, progression-free survival, toxicity, and quality of life. An integrated economic evaluation will determine the cost per quality of life year gained using SABR (vs. SOC) and a translational component will enable identification of predictive/prognostic biomarkers of the oligometastatic state.

Начало: 01.11.2019 Край: 31.12.2030 Възраст: от 18 г. Лечение

Australia, Canada, Ireland +1 British Columbia Cancer Agency NCT03862911

Активно (без набиране) Фаза 2

Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors

Metastatic Solid Tumor

The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy, in participants with metastatic (cancer that has spread) solid tumors.

Начало: 15.10.2019 Край: 01.12.2026 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +5 Gilead Sciences NCT03964727

Активно (без набиране) Фаза 2

Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer

Cutaneous Squamous Cell Carcinoma Advanced Cutaneous Squamous Cell Carcinoma Metastatic Cutaneous Squamous Cell Carcinoma

To estimate the clinical benefit of cemiplimab monotherapy versus cemiplimab in combination with RP1 for patients with locally advanced or metastatic CSCC, as assessed by overall response rate (ORR) and complete response rate (CRR) according to blinded independent review.

Начало: 08.10.2019 Край: 01.09.2025 Възраст: от 18 г. Лечение

Australia, Bulgaria, Canada +7 Replimune, Inc. NCT04050436

1 … 89 90 91 92 93 … 100